Case number | Year case ID | PK-resistant PrPD | Gender, female (%) | Race, white (%) | Age at onset (years) | Disease duration (months) | Cases found by retrospective studyb | Available frozen tissue subcortical regions | ||
---|---|---|---|---|---|---|---|---|---|---|
Type 1–2 (%) | T2a (%) | |||||||||
Brain | Crbl | |||||||||
pGM-CJD | ||||||||||
1 | 2015 | 1–2 | 98 | ND | − | + | 63 | 12 | Yes | Yes |
2 | 2016 | 1–2 | 89 | 100 | + | + | 73 | 4 | Yes | Yes |
3 | 2015 | 1–2 | 45 | 10 | − | + | 68 | 24 | Yes | Yes |
4 | 2016 | 1–2 | 29 | 0 | + | + | 71 | 2 | Yes | Yes |
5 | 2015 | 1–2 | 26 | 0 | − | + | 57 | 2 | Yes | Yes |
6 | 2016 | 1–2 | 16 | 0 | + | + | 60 | 2 | Yes | Yes |
7 | 2014 | 1–2 | 3 | 0 | + | + | 83 | 2 | Yes | Yes |
2015–16 | 100 | 44 ± 36e | 18 ± 40e | 57 | 100 | 67 ± 9e | 7 ± 8e | 100% | 100% | |
pWM-CJD | ||||||||||
8 | 2017 | 1–2 | 60 | ND | + | + | 72 | 9 | Yes | Yes |
9c | 2005 | 1–2 | 50 | 0 | − | + | 54 | 11 | No | Yes |
10d | 2018 | 1–2 | 40 | 0 | − | − | 69 | 7 | No | Yes |
11c | 2003 | 1–2 | 24 | 0 | − | + | 52 | 11 | No | Yes |
12c | 2006 | 1–2 | 8 | 0 | − | + | 59 | 7 | No | Yes |
13 | 2015 | 1–2 | 5 | ND | − | + | 75 | 1 | Yes | Yes |
14d | 2019 | 1–2 | 5 | 0 | − | + | 51 | 7 | No | Yes |
15 | 2016 | 1–2 | 4 | 0 | + | + | 72 | 9 | Yes | Yes |
16c | 2010 | 1–2 | 2 | 0 | − | + | 57 | 13 | No | Yes |
17 | 2015 | 1 | 0 | 0 | − | + | 62 | 7 | Yes | Yes |
18 | 2016 | 1 | 0 | 0 | − | + | 44 | 3 | Yes | Yes |
19c | 2011 | 1 | 0 | 0 | − | U | 76 | 5 | No | No |
20 | 2013 | 1 | 0 | NA | − | + | 68 | 2 | Yes | No |
21 | 2016 | 1 | 0 | 0 | + | + | 50 | 11 | Yes | No |
2003–19 | 64 | 14 ± 21e,f | 0 | 21 | 92 | 61.5 ± 10.5e | 7 ± 4e | 50% | 79% |
Case number | Age at onset (years) | Disease duration (months) | PrP immunostaining pattern | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
MM2-like CC (%)d | Plaques | |||||||||||
CCe,f | Subce,f | Cerebellum | ||||||||||
PK-resistant PrPD | Grey matter | White matter | Coarse | “Brush stroke-like” | ||||||||
T121 (%)a | T2 (%)b, c | Mol. L | Grl. L.g | Crbl Mol. L | Crbl Mol. L | |||||||
pGM-CJD | ||||||||||||
1 | 63 | 12 | 0 | 98 | 90 | 0 | 0 | 3 | 1 | 0 | + | − |
2 | 73 | 4 | 0 | 89 | 53 | 0 | 0 | 2 | 0.5 | 0 | + | + |
3 | 68 | 24 | 0 | 45 | 90 | 0 | 0 | 1 | 0.5 | 0 | + | + |
4 | 71 | 2 | 0 | 29 | 20 | 0 | 0 | 1.5 | 1 | 0 | − | + |
5 | 57 | 2 | 0 | 26 | 40 | 0 | 0 | 2 | 1 | 0 | − | + |
6 | 60 | 2 | 0 | 16 | 43 | 1 | 0 | 3 | 2 | 0.1 | − | + |
7 | 83 | 2 | 0 | 3 | 5 | 0 | 0 | 0 | 1 | 0.1 | − | + |
Mean ± SD | 68 ± 9 | 7 ± 8 | 0 | 44 ± 36 | 49 ± 32 | 0.1 ± 0.4 | 0 | 1.8 ± 1.1 | 1 ± 0.5 | 0.03 ± 0.05 | 43h (3/7) i | 86h (6/7) i |
pWM-CJD | ||||||||||||
8 | 72 | 9 | 67 | 60 | 80 | 0.5 | 1.5 | 0 | 0 | 2 | + | + |
9 | 54 | 11 | 55 | 50 | 57 | 1.5 | 2 | 0 | 0 | 2 | + | − |
10 | 69 | 7 | 23 | 40 | 37 | 0.5 | 2 | 0 | 0 | 2 | + | + |
11 | 52 | 11 | 65 | 24 | 20 | 1 | 1.5 | 0 | 0 | 2 | − | + |
12 | 59 | 7 | 25 | 8 | 10 | 2 j | 1.5 | 0 | 0 | 1 | + | + |
13 | 75 | 1 | 62 | 5 | 5 | 0.5 | 1 | 0 | 0 | 1 | − | + |
14 | 51 | 7 | 52 | 5 | 0 | 0.5 | 1 | 0 | 0 | 1 | − | + |
15 | 72 | 9 | 27 | 4 | 30 | 0.5 | 3 | 0 | 0 | 2 | + | + |
16 | 57 | 13 | 46 | 2 | 0 | 3 j | 3 | 0 | 0 | 3 | − | + |
17 | 62 | 7 | 56 | 0 | 0 | 2 | 3 | 0 | 0 | 2 | − | + |
18 | 44 | 3 | 22 | 0 | 0 | 1.5 | 1.5 | 0 | 0 | 0.5 | − | + |
Mean ± SD | 61 ± 10 | 8 ± 3.5 | 45 ± 18 | 18 ± 22 | 22 ± 27 | 1.2 ± 0.8 | 1.9 ± 0.8 | 0 | 0 | 1.7 ± 0.7 | 45h (5/11)i | 91h (10/11)i |
P value | NS | NS | < 0.0001 | NS | NS | < 0.007 | < 0.0001 | < 0.005 | < 0.002 | < 0.0001 | NSk | NSl |
Prion disease | pGM-CJD (n = 7) | pWM-CJD (n = 14) | sCJD (n = 21)a | Significance | Statistical test |
---|---|---|---|---|---|
Female | 57b (4/7)c | 21 (3/14) | 38 (8/21) | NS | Fisher’s exact test |
Race/ethnicity | |||||
White | 100 (7/7) | 92 (12/13) | 90 (17/19) | Chi-square | |
Asian | 0 (0/7) | 8 (1/13) | 5 (1/19) | ↓ | |
Other | 0 (0/7) | 0 (0/13) | 5 (1/19) | Fisher’s exact test | |
Age at onset (years)d | 67 ± 9 | 61.5 ± 10.5 | 64 ± 10 | One way ANOVA | |
Disease duration (months)d | 7 ± 8 | 7 ± 4 | 6 ± 6 | ↓ | |
Presentatione | |||||
Cognitive | 67 (4/6) | 75 (9/12) | 53 (9/17) | Fisher’s exact test | |
Cerebellar | 0 (0/6) | 8 (1/12) | 24 (4/17) | ↓ | |
Sensory | 17 (1/6) | 8 (1/12) | 6 (1/17) | ↓ | |
Psychiatric | 33 (2/6) | 17 (2/12) | 0 (0/17) | ↓ | |
Otherf | 0 (0/6) | 17 (2/12) | 12 (2/17) | ↓ | |
Family history of prion disease | 0 (0/7) | 0 (0/9) | 0 (0/21) | ↓ | |
Family history of neurodegenerative disease | 14 (1/7) | 0 (0/9) | 5 (1/21) | ↓ | |
Positive CSF 14-3-3 | 50 (2/4) | 50 (4/8) | 94 (15/16) | < 0.03 g | ↓ |
Total tau [pg/ml] × 1000d | 5.5 ± 3.1 (n = 4) | 3.1 ± 3.8 (n = 7) | 5.8 ± 3.7 (n = 13) | NS | One way ANOVA |
Positive RT-QuIC | 80 (4/5) | 100 (5/5) | 86 (6/7) | Fisher’s exact test | |
Brain MRI suggestive of CJD | 100 (3/3) | 100 (6/6) | 88 (14/16) | ↓ | |
EEG with PSWCs | 0 (0/2) | 50 (3/6) | 25 (3/12) | ↓ |